Small Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Personalis
PSNL
$1.84B
| $1.84B | $17.25 | 1.11% |
|
|
FRNM
2
Freenome Inc
FRNM
$1.5B
| $1.5B | $13.99 | 1.52% |
|
3
Opko Health
OPK
$1.11B
| $1.11B | $1.49 | 0.68% |
|
4
Castle Biosciences
CSTL
$1.07B
| $1.07B | $35 | 4.57% |
|
5
Fulgent Genetics
FLGT
$549M
| $549M | $19.95 | 2.57% |
|
6
Myriad Genetics
MYGN
$305M
| $305M | $3.19 | 4.59% |
|
7
Biodesix
BDSX
$296M
| $296M | $28.07 | 10.6% |
|
Small Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 7 small cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $250M and $2B — worth a combined $6.68B.
The largest by market cap are Personalis (PSNL) at $1.84B, Freenome Inc (FRNM) at $1.5B and Opko Health (OPK) at $1.11B.
Among institutional investors, Personalis (PSNL) drew the most net new fund positions in Q2 2026: 43 funds opened new positions, taking total fund holders up 19 (14%) quarter-over-quarter.
- Combined market cap: $6.68B across 7 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: Personalis (PSNL), $1.84B market cap.
- Most net new fund positions in Q2 2026: Personalis (PSNL), +19 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.